Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 16, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Avanir Pharmaceuticals (NASDAQ: AVNR), Sirona Dental Systems Inc. (NASDAQ: SIRO), Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Genomic Health Inc. (NASDAQ: GHDX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quest Diagnostics Inc. Research Report
On December 6, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that its Board of Directors has declared a quarterly cash dividend in the amount of $0.30 per share. The Company informed that the dividend will be payable on January 22, 2014 to shareholders of record of Quest Diagnostics common stock on January 7, 2014. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Avanir Pharmaceuticals Research Report
On December 10, 2013, Avanir Pharmaceuticals, Inc. (Avanir) announced results from PRIME, a phase II clinical trial of the investigational drug AVP-923, for the treatment of central neuropathic pain in patients with multiple sclerosis. According to the Company, PRIME did not meet the primary efficacy endpoint. In the study, patients treated with AVP-923 experienced levels of pain reduction commensurate with those observed in similar studies and the improvement in pain scores from baseline reached statistical significance; however, there was no difference between the treatment arms and placebo. Avanir stated that it plans to review the detailed data from the PRIME study in conjunction with previously generated data in diabetic peripheral neuropathic pain to determine next steps for the development of AVP-923 in neuropathic pain. The Full Research Report on Avanir Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Sirona Dental Systems Inc. Research Report
On December 1, 2013, Sirona Dental Systems Inc. (Sirona) issued a press release providing highlights from the 2013 ADF dental exhibition in Paris, where the Company once again presented its full range of equipment for dental practices and labs. According to Sirona, its new intraoral camera APOLLO DI and the presentation of the continuous digital process chain at the Company stand interested many attendees. "The key topic at the ADF 2013 was definitely digital impression taking: It is and will remain the basis for a fast, simple, efficient workflow between the dental practice and the lab. With the new APOLLO DI impression-taking system, Sirona offers dentists a highly economical entry into digital impression taking," explained Lionel Phelipot, General Manager of Sirona France. "The inexpensive APOLLO DI features easy handling, precise acquisition and the tried-and-tested Sirona Connect workflow The impression-taking system consists of an acquisition unit, the APOLLO Connect software and the APOLLO DI intraoral camera, with which users can record live digital impressions of a clinical situation." The Full Research Report on Sirona Dental Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Ligand Pharmaceuticals Incorporated Research Report
On December 9, 2013, Ligand Pharmaceuticals Inc. (Ligand) announced positive preclinical data on small-molecule G-CSF receptor agonist at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans. In preclinical studies, Ligand evaluated the ability of LGD-7455 to stimulate neutrophil (white blood cell) counts in cynomolgus monkeys and investigated the role that metal ions play in the activity of LGD-7455 on the G-CSF receptor (G-CSFR). Additionally, Ligand examined effects and mechanisms of LGD-7455 on tumor cell growth. "We are pleased to present this scientifically important work from one of Ligand's internal un-partnered programs," said Matthew W. Foehr, Chief Operating Officer of Ligand. "Ligand's R&D team continues to make scientific advancements like this first reported proof-of-concept for a small molecule G-CSF in a primate model. Further optimization of the LGD-7455 series may lead to a novel oral anticancer therapy that also serves as a supportive care agent to treat neutropenia in patients receiving bone-marrow suppressive treatments." The Full Research Report on Ligand Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Genomic Health Inc. Research Report
On December 4, 2013, Genomic Health, Inc. (Genomic Health) announced that the Company will present results from multiple Oncotype DX® breast cancer test studies at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, being held from December 10 to December 14, 2013 at the Henry B. Gonzalez Convention Center. The Company informed that the presentations include results from a comparison of risk classification between the Oncotype DX breast cancer test and other genomic assays. The Full Research Report on Genomic Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.http://www.AnalystsCorner.com
©2012 PR Newswire. All Rights Reserved.